PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/00 — A2

(11) International Publication Number: **WO 00/62765**

(43) International Publication Date: 26 October 2000 (26.10.00)

(21) International Application Number: PCT/GB00/01380

(22) International Filing Date: 11 April 2000 (11.04.00)

(30) Priority Data:
60/129,901 16 April 1999 (16.04.99) US

(71) Applicant *(for all designated States except US)*: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BARLAAM, Bernard, Christophe [FR/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). PISER, Timothy, Martin [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US).

(74) Agent: PHILLIPS, Neil, Godfrey, Alasdair; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: ESTROGEN RECEPTOR-β LIGANDS

(57) Abstract

A method for treating a disease associated with the estrogen receptor-β, comprising the step of administering a therapeutically - effective amount of a compound that satisfies the equation: $(K_{i\alpha A}/Ki_{\beta A})/(K_{i\alpha E}/K_{i\beta E})>1$, optionally having the general structure (I).



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ESTROGEN RECEPTOR-β LIGANDS

Technical Field

The present invention is directed to a series of ligands, and more particularly to estrogen receptor-β ligands which have better selectivity than estrogen for the estrogen receptor-β over the estrogen receptor–α, as well as to methods for their production and use in the treatment of diseases related to the estrogen receptor–β, specifically, Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis, or prostate cancer.

Background

Estrogen-replacement therapy ("ERT") reduces the incidence of Alzheimer's disease and improves cognitive function in Alzheimer's disease patients (Nikolov *et al.* Drugs of Today, 34(11), 927-933 (1998)). ERT also exhibits beneficial effects in osteoporosis and cardiovascular disease, and may have anxiolytic and anti-depressant therapeutic properties. However, ERT shows detrimental uterine and breast side effects that limit its use.

The beneficial effects of ERT in post-menopausal human women is echoed by beneficial effects of estrogen in models relevant to cognitive function, anxiety, depression, bone loss, and cardiovascular damage in ovariectomized rats. Estrogen also produces uterine and breast hypertrophy in animal models reminiscent of its mitogenic effects on these tissues in humans.

The beneficial effects of ERT in post-menopausal human women is echoed by beneficial effects of estrogen in models relevant to cognitive function, anxiety, depression, bone loss, and cardiovascular damage in ovariectomized rats. Specifically, experimental studies have demonstrated that estrogen effects the central nervous system ("CNS") by increasing cholinergic function, increasing neurotrophin / neurotrophin receptor expression, altering amyloid precursor protein processing, providing neuroprotection against a variety of insults, and increasing glutamatergic synaptic transmission, among other effects. The overall CNS profile of estrogen effects in pre-clinical studies is consistent with its clinical utility in improving cognitive function and delaying Alzheimer's disease progression. Estrogen also produces mitogenic effects in uterine and breast tissue indicative of its detrimental side effects on these tissues in humans.

The estrogen receptor ("ER") in humans, rats, and mice exists as two subtypes, ER-α and ER-β, which share about a 50% identity in the ligand-binding domain (Kuiper *et al.* Endocrinology 139(10) 4252-4263 (1998)). The difference in the identity of the subtypes accounts for the fact that some small compounds have been shown to bind preferentially to one subtype over the other (Kuiper *et al.*).

In rats, ER-β is strongly expressed in brain, bone and vascular epithelium, but weakly expressed in uterus and breast, relative to ER-α. Furthermore, ER-α knockout (ERKO-α) mice are sterile and exhibit little or no evidence of hormone responsiveness of reproductive tissues. In contrast, ER-β knockout (ERKO-β) mice are fertile, and exhibit normal development and function of breast and uterine tissue. These observations suggest that selectively targeting ER-β over ER-α could confer beneficial effects in several important human diseases, such as Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, and cardiovascular disease without the liability of reproductive system side effects. Selective effects on ER-β-expressing tissues (CNS, bone, etc.) over uterus and breast could be achieved by agents that selectively interact with ER-β over ER-α.

It is a purpose of this invention to identify ER-β-selective ligands that are useful in treating diseases in which ERT has therapeutic benefits.

It is another purpose of this invention to identify ER-β-selective ligands that mimic the beneficial effects of ERT on brain, bone and cardiovascular function.

It is another purpose of this invention to identify ER-β-selective ligands that increase cognitive function and delay Alzheimer's disease progression.

Summary of the Invention

This present invention is directed to the use of compounds having the generic structure:



as ER-β-selective ligands. which mimic ERT, but lack undesirable side effects of ERT. These compounds particularly satisfy the formula:

$(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 1$,

preferably:

$(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 30$.

more preferably:

$(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 100$,

wherein $K_{i\alpha A}$ is the K_i value for the ligand in ER-α; $K_{i\beta A}$ is the Ki value for the ligand in ER-β: $K_{i\alpha E}$ is the K_i value for estrogen in ER-α; and $K_{i\beta E}$ is the K_i value for estrogen in ER-β.

Detailed Description of the Invention

The instant invention involves a method for treating a disease associated with the estrogen receptor-β, comprising the step of administering a therapeutically-effective amount of a compound that satisfies the equation $(K_{i\alpha A}/Ki_{\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 1$, wherein $K_{i\alpha A}$ is the K_i value for the agonist in ER-α; $K_{i\beta A}$ is the K_i value for the agonist in ER-β; $K_{i\alpha E}$ is the K_i value for estrogen in ER-α; and $K_{i\beta E}$ is the K_i value for estrogen in ER-β. Preferably, the compound satisfies the equation $(K_{i\alpha A}/Ki_{\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 100$. Preferred deseases associated with the estrogen receptor-β are selected from Alzheimer's disease. anxiety disorders, depressive disorders. osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer. More preferably, the diseases are Alzheimer's disease or depressive disorders.

The compounds of the instant invention are ER-β-selective ligands of the structure:



In this structure L^1 is -C(=O)-, $=C(R^6)$-, $-CH(R^6)$-, O, S, or NR^a, preferably -C(=O)-, $=C(R^6)$-, $-CH(R^6)$- or O; L^2 is =C- or -CH-; L^3 is $=C(R^6)$-, $-CH(R^6)$- or -C(=O)-; and L^4 is -C(=O)-, CH_2, O, S, or NR^a, preferably -C(=O)-, CH_2 or O, provided that when L^1 is -C(=O)-, L^4 is CH_2, O, S, or NR^a; when L^4 is -C(=O)-, L^1 is CH_2, O, S, or NR^a; and when L^3 is -C(=O)-, L^1 is $=C(R^6)$- or $-CH(R^6)$-, and L^4 is O or NR^a. Additionally, when L^1 is $=C(R^6)$-, L^2 is =C-; when L^1 is $-CH(R^6)$-, L^2 is -CH-; when L^3 is $=C(R^6)$-, L^2 is =C-; and when L^3 is $-CH(R^6)$-, L^2 is -CH-. ═ represents a single bond or double bond, depending upon the hybridization of L^1-L^4. The structures for L^2 show only three bonds because the fourth bond is a single bond to R^1.

R^1 is attached via a single bond to L^2, and is phenyl, substituted phenyl, Het, or substituted Het, as defined below. R^1 is preferably:



wherein: R^7 is H, Cl, or methyl; R^8 is Br, Cl, F, R^a, OR^a, or allyl; R^9 is H, OH, NH_2, Br, Cl; and R^{10} is H or methyl; or R^8 and R^9 may combine to be $-OCH_2O-$, forming a secondary 5-membered ring structure exterior to the phenyl group; or R^1 is a substituted or unsubstituted heterocyclic substituent having the following structure:



; more preferably unsubstituted


R^2, R^3, R^4, and R^5 are each, independently, $-R^a$, $-OR^a$, $-SR^a$, $-NR^aR^a$, $-NC(=O)R^a$, $-NS(=O)R^a$, $-NS(=O)_2R^a$, halogen, cyano, $-CF_3$, $-CO_2R^a$, $-C(=O)R^a$, $-C(=O)NHR^a$, nitro, $-S(=O)R^a$, or $-S(=O)_2R^a$, and is preferably R^a, OR^a, NR^a_2, $NC(=O)R^a$, CF_3, or halogen, preferably, hydrogen, hydroxyl or methyl.

R^6 is R^a, phenyl or CF_3.

R^a is, independently, at each occurrence, H or $(C_1$-$C_5)$alkyl.

When L^1 is -C(=O)-, and R^2 is hydroxy or hydrogen, and R^3 is hydrogen, and R^4 is hydroxy, and R^5 is hydrogen, and R^6 is hydrogen, then R^1 is not para-phenol.

For purposes of this invention, "substituted" when used to modify a phenyl or a heteroatomic ring means such a ring substituted at one or more positions, independently, with -R^a, -OR^a, -SR^a, -NR^aR^a, -$NC(=O)R^a$, -$NS(=O)R^a$, -$NS(=O)_2R^a$, halogen, cyano, -CF_3, -CO_2R^a, -$C(=O)R^a$, -$C(=O)NHR^a$, nitro, -$S(=O)R^a$, or -$S(=O)_2R^a$.

Also, for purposes of this invention, "Het" means a substituted or unsubstituted one- or two-ring heterocycle selected from the following:



wherein the crossed bond represents that the heterocycle may be attached at any available position on the ring that it crosses.

Estrogen Receptor Binding Measurements

The ability of a compound to bind to ER was measured by its ability to compete for binding with the radio-labeled estrogen, [^{125}I]-16α–iodo–3,17β–estradiol (NEN, Cat.#NEX-144). The radio-ligand is hereafter referred to as [^{125}I]-estradiol.

ER-β (Gen Bank Accession #X99101) or ER-α (Gen Bank Accession #M12674) cDNAs were cloned into the expression vector pSG5 (Stratagene), transformed into *e. coli* strain DHαF', and purified using anion-exchange resin columns (Qiagen Cat.#12125). Receptor protein was prepared by *in vitro* transcription and translation of these plasmids using the TNT T7 Quick-Coupled reticulocyte lysate system (Promega Cat.#L1170). Reticulocyte lysate (12.5 mL) was incubated for 90 min at 30 °C with 312.5 μg of ER-α and 625 μg of ER-β plasmids. Programmed lysate was then aliquotted and stored frozen at -80 °C.

Compounds were tested in duplicate at half-log concentrations ranging from 10 pM to 3 μM. Compounds were prepared as 1 mM stocks in DMSO, then diluted in the binding-assay buffer (in mM: 20 HEPES, 150 NaCl, 1 EDTA, 6 monothioglycerol and 10 Na_2MoO_4; 10% wt/vol glycerol, and pH = 7.9) to a series of three-fold concentrated, 20 μL aliquots in a 96-well plate. Receptor aliquots were thawed on ice, and appropriately diluted (see below) in binding assay buffer. Diluted receptor (30 μL/each) was added to each well. [^{125}I]-estradiol was diluted from the manufacturer's ethanol stock solution to a 900 pM working solution in binding-assay buffer. The final assay volume was 60 μL, consisting of 20 μL of a compound according to the instant invention, 30 μL of programmed reticulocyte lysate, and 10 μL of 900 pM [^{125}I]-estradiol. The final concentration of [^{125}I]-estradiol was 150 pM. Plates containing the final assay mixture were mixed on a shaker for 2 min and incubated overnight (~16 h) at 4 °C.

Receptor-bound and unbound radioligand was separated by filtration over sephadex columns. Columns (45 μL bed volume) were prepared by adding dry column media (Pharmacia Cat#G-25) to 96-well column templates (Millipore MultiScreen Plates Cat#MAHVN4510). Columns were then saturated with 300 μL of binding-assay buffer and stored at 4 °C. Prior to use, stored columns were spun for 10 minutes at 2000 RPM, then washed twice with 200 μL of fresh binding buffer. The binding-assay mixtures (50 μL/each) were then applied to the columns, and an additional elution volume of 35 μL was immediately applied to the column. Receptor-bound radioligand was then eluted from the column by

centrifugation for 10 minutes at 2000 RPM. A scintillation cocktail (145 µL) was added to the eluted radioligand/receptor complex, and radio-label was measured by liquid scintillation counting.

Non-specific binding was defined by competition with 150 nM diethylstilbesterol (DES). Binding affinities are expressed as K_i, calculated using the Cheng-Prushoff formula according to IC_{50} values generated by fitting the relationship of concentration to percent specific binding (SB) with the following equation:

$$\% SB = Maximum - (Maximum - Minimum)/(1+10^{(logIC50-log[Compound])})$$

In this assay, standard estrogen receptor ligands estradiol and DES were detected as high-affinity (K_i<1 nM), non-selective ligands of ER-β and ER-α.

The volume of receptor-programmed reticulocyte lysate to be added to the binding assay was determined independently from two measurements made on each batch of receptor prepared. First, K_is were determined for standard compounds using a series of dilutions of the receptor preparation. Scatchard analysis of ligand binding affinity was performed at the receptor dilutions that produced reported K_is for these compounds and an acceptable signal:noise ratio (~10). These experiments indicated a K_D for [^{125}I]-estradiol of 0.1-1 nM, and a B_{max} of 5-30 pmol.

Administration and Use

Compounds of the present invention are shown to have high selectivity for ER-β over ER-α, and may possess agonist activity on ER-β without undesired uterine effects. Thus, these compounds, and compositions containing them, may be used as therapeutic agents in the treatment of various CNS diseases related to ER-β, such as, for example, Alzheimer's disease.

The present invention also provides compositions comprising an effective amount of compounds of the present invention, including the nontoxic addition salts, amides and esters thereof, which may, serve to provide the above-recited therapeutic benefits. Such compositions may also be provided together with physiologically-tolerable liquid, gel or solid diluents, adjuvants and excipients. The compounds of the present invention may also be combined with other compounds known to be used as therapeutic agents for the above or other indications.

These compounds and compositions may be administered by qualified health care professionals to humans in a manner similar to other therapeutic agents and, additionally, to

other mammals for veterinary use, such as with domestic animals. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active ingredient is often mixed with diluents or excipients which are physiologically tolerable and compatible with the active ingredient. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH-buffering agents, and the like.

The compositions are conventionally administered parenterally, by injection, for example, either subcutaneously or intravenously. Additional formulations which are suitable for other modes of administration include suppositories, intranasal aerosols, and, in some cases, oral formulations. For suppositories, traditional binders and excipients may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained-release formulations, or powders.

The present compounds may be formulated into the compositions as neutral or salt forms. Pharmaceutically-acceptable nontoxic salts include the acid addition salts (formed with the free amino groups) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

In addition to the compounds of the present invention that display ER-β activity, compounds of the present invention can also be employed as intermediates in the synthesis of such useful compounds.

Synthesis

Compounds within the scope of the present invention may be synthesized chemically by means well known in the art. The following Examples are meant to show general synthetic schemes, which may be used to produce many different variations by employing various commercially-available starting materials. These Examples are meant only as guides on how to make some compounds within the scope of the invention, and should not be interpreted as limiting the scope of the invention.

Examples

Example 1 (Route A)

-(3-Bromo-4-hydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one

1,3,5-Trihydroxybenzaldehyde (1.01 g, 6.25 mmol) and 3-bromo-4-hydroxyphenylacetic acid (1.44 g, 6.25 mmol) were suspended in $POCl_3$ (4 mL). After 1 min, an exothermic reaction occured. The mixture was allowed to cool to room temperature. Zinc chloride (1M ether solution, 4.7 mmol) was added and the mixture was heated at 75 °C for 1 h. After cooling, the mixture was partitioned in ethyl acetate and 1M aqueous HCl. The organic layer was washed with brine and dried with $MgSO_4$. Purification on silica gel (MeOH/dichloromethane, gradient) afforded 1-(2,4,6-trihydroxyphenyl)-2-(3-bromo-4-hydroxyphenyl)ethanone (390 mg) as a tan solid.

To 1-(2,4,6-trihydroxyphenyl)-2-(3-bromo-4-hydroxyphenyl)ethanone (370 mg) in DMF (5 mL) under nitrogen was added BF_3-Et_2O (0.83 mL, 6.55 mmol) dropwise, followed by methanesulfonyl chloride (0.507 mL, 6.55 mmol). The mixture was stirred at room temperature for 10 min and heated at 55 °C for 30 min. After cooling, the mixture was partitioned in ethyl acetate / 1M aqueous HCl. The organic layer was washed with 1M HCl and brine, and purified by C_{18} HPLC to give the title compound (55 mg).

Example 2 (Compound No. 28; Route B)

3-(4-hydroxyphenyl)-7-hydroxy-4-methylcoumarin

A solution of 2,4-dihydroxyacetophenone (1.1 g, 7.24 mmol), 4-hydroxyphenylacetic acid (1.45 g, 9.5 mmol) and potassium acetate (0.9 g, 9.2 mmol) in acetic anhydride (10 mL) was heated under reflux for 18 h. After cooling, the mixture was poured into ice and water. The solid was filtered, washed with ether and dried under vacuum to give 3-(4-acetoxyphenyl)-7-acetoxy-4-methylcoumarin (1.83 g).

A suspension of 3-(4-acetoxyphenyl)-7-acetoxy-4-methylcoumarin (500 mg) in THF (10 mL) and 1N aqueous sodium hydroxide (10 mL) was stirred for 1 h. The mixture is acidified to pH = 1 with concentrated HCl and extracted with EtOAc / water. The organic layer was washed with brine and dried over $MgSO_4$. Evaporation of the solvent and trituration of the residue with ether gave the title compound (140 mg).

The HPLC conditions (HPLC 4.6 x 250 mm C_{18} 5 µm Vydax 218TP54 column, flow rate: 1.5 mL/min, acetonitrile/water 0.1% TFA linear gradient from 10:90 to 50:50 over 30 min. UV detection: 254 nm) are referred as conditions A.

The HPLC conditions (HPLC 2.1 x 30 mm C_{18} 3.5 µm Zorbax Rapid Resolution column, flow rate: 0.7 mL/min, water - 0.05% TFA for 0.5 min, then 90% aqueous acetonitrile/water 0.05% TFA linear gradient from 0:100 to 80:20 over 9.5 min, UV detection) are referred as conditions B.

The following compounds were prepared according to these routes, using the relevant starting materials.



Table 1.

No.	L^1	L^2	L^3	L^4	R^1
1	C(=O)	=C-	$=CR^6$-	O	3,4-dihydroxyphenyl
2	C(=O)	=C-	$=CR^6$-	O	2-Cl-4-hydroxyphenyl
3	C(=O)	=C-	$=CR^6$-	O	2-Me-4-hydroxyphenyl
4	C(=O)	=C-	$=CR^6$-	O	3-F-4-hydroxyphenyl
5	C(=O)	=C-	$=CR^6$-	O	3-Cl-4-hydroxyphenyl
6	C(=O)	=C-	$=CR^6$-	O	3-Br-4-hydroxyphenyl
7	C(=O)	=C-	$=CR^6$-	O	3-allyl-4-hydroxyphenyl
8	C(=O)	=C-	$=CR^6$-	O	3-Pr-4-hydroxyphenyl

No.	L^1	L^2	L^3	L^4	R^1
9	C(=O)	=C-	$=CR^6$-	O	3-methoxy-4-hydroxyphenyl
10	C(=O)	=C-	$=CR^6$-	O	3,5-diMe-4-hydroxyphenyl
11	C(=O)	=C-	$=CR^6$-	O	4-fluorophenyl
12	C(=O)	=C-	$=CR^6$-	O	3,4-(OCH_2O)phenyl
13	C(=O)	=C-	$=CR^6$-	O	4-aminophenyl
14	C(=O)	=C-	$=CR^6$-	O	2-naphthyl
15	C(=O)	=C-	$=CR^6$-	O	3-hydroxyphenyl
16	C(=O)	=C-	$=CR^6$-	O	2-hydroxyphenyl
17	C(=O)	=C-	$=CR^6$-	O	2-thiophene
18	C(=O)	=C-	$=CR^6$-	O	3-thiophene
19	C(=O)	=C-	$=CR^6$-	O	2-quinolinyl
20	C(=O)	=C-	$=CR^6$-	O	4-bromophenyl
21	C(=O)	=C-	$=CR^6$-	O	4-chlorophenyl
22	C(=O)	=C-	$=CR^6$-	O	4-hydroxyphenyl
23	C(=O)	=C-	$=CR^6$-	O	4-hydroxyphenyl
24	C(=O)	=C-	$=CR^6$-	O	3-F-4-hydroxyphenyl
25	C(=O)	=C-	$=CR^6$-	O	4-hydroxyphenyl
26	C(=O)	-CH-	$-CHR^6$-	O	4-hydroxyphenyl
27	C(=O)	-CH-	$-CHR^6$-	CH_2	4-hydroxyphenyl
28	$=CR^6$-	=C-	C(=O)	O	4-hydroxyphenyl
29	$=CR^6$-	=C-	C(=O)	O	4-hydroxyphenyl
30	$=CR^6$-	=C-	C(=O)	O	4-hydroxyphenyl
31	$=CR^6$-	=C-	C(=O)	O	2-thiophene
32	C(=O)	=C-	$=CR^6$-	O	4-hydroxyphenyl
33	C(=O)	=C-	$=CR^6$-	O	2-F-phenyl
34	C(=O)	=C-	$=CR^6$-	O	phenyl
35	C(=O)	=C-	$=CR^6$-	O	phenyl
36	O	=C-	$=CR^6$-	C(=O)	4-hydroxyphenyl

No.	L^1	L^2	L^3	L^4	R^1
37	CH_2	-CH-	$-CHR^6-$	C(=O)	4-hydroxyphenyl
38	$=CR^6-$	=C-	C(=O)	O	4-hydroxyphenyl
39	$=CR^6-$	=C-	C(=O)	O	4-hydroxyphenyl
40	$=CR^6-$	=C-	C(=O)	O	4-hydroxyphenyl
41	$=CR^6-$	=C-	C(=O)	O	4-hydroxyphenyl
42	$=CR^6-$	=C-	C(=O)	O	4-Cl-phenyl
43	$=CR^6-$	=C-	C(=O)	O	4-hydroxyphenyl
44	C(=O)	=C-	$=CR^6-$	O	4-isopropoxyphenyl
45	C(=O)	-CH-	$-CHR^6-$	CH_2	3-Br-phenyl
46	CH_2	-CH-	$-CHR^6-$	O	4-hydroxyphenyl

(Continuation of Table 1)

No.	R^2	R^3	R^4	R^5	R^6
1	OH	H	OH	H	H
2	OH	H	OH	H	H
3	OH	H	OH	H	H
4	OH	H	OH	H	H
5	OH	H	OH	H	H
6	OH	H	OH	H	H
7	OH	H	OH	H	H
8	OH	H	OH	H	H
9	OH	H	OH	H	H
10	OH	H	OH	H	H
11	OH	H	OH	H	H
12	OH	H	OH	H	H
13	OH	H	OH	H	H
14	OH	H	OH	H	H
15	OH	H	OH	H	H
16	OH	H	OH	H	H

No.	R^2	R^3	R^4	R^5	R^6
17	OH	H	OH	H	H
18	OH	H	OH	H	H
19	OH	H	OH	H	H
20	OH	H	OH	H	H
21	OH	H	OH	H	H
22	OH	H	OMe	H	H
23	Me	H	OH	H	H
24	H	H	OH	H	H
25	H	H	OH	H	CF_3
26	OH	H	OH	H	H
27	OH	H	OH	H	H
28	H	H	OH	H	Me
29	H	H	OH	H	Et
30	H	H	H	H	H
31	H	H	OH	H	H
32	OH	H	OH	OMe	H
33	OH	H	OH	H	H
34	OH	H	OH	H	Ph
35	H	H	OH	H	Ph
36	H	H	OH	H	H
37	H	H	OH	H	H
38	H	H	OH	H	H
39	OH	H	OH	H	H
40	H	H	H	OH	H
41	H	OH	H	H	H
42	H	H	OH	H	Me
43	H	H	OH	Me	Me
44	H	H	OH	H	CF_3
45	H	H	OH	H	H

No.	R^2	R^3	R^4	R^5	R^6
46	H	H	OH	H	H

Table 2. Purification, Properties, and Synthetic Route

No.	HPLC min (method)	MS (MH^+)	ER-β K_i nM	ER-α K_i nM	Synthetic Route
1			2.15	605	*
2	5.76 (B)	305 (^{35}Cl)	0.55	56	A
3	5.41 (B)	285	1.2	61	A
4	5.62 (B)	289	0.5	74	A
5	6.11 (B)	305 (^{35}Cl)	1.2	1100	A
6	25.6 (A)	349 (^{79}Br)	1.25	439	A
7	6.72 (B)	311	3.2	>3000	A
8	7.08 (B)	313	0.75	>3000	A
9			143	>3000	*
10	25.4 (A)	299	25	>3000	A
11	6.93 (B)	273	100	>3000	A
12			22	>3000	*
13			6	>3000	*
14	7.86 (B)	305	150	>3000	A
15	5.39 (B)	271	15	900	A
16	5.68 (B)	271	110	>3000	A
17	^1H NMR (DMSO-d_6): 12.59 (s, 1H), 10.99 (s, 1H), 8.88 (s, 1H), 7.63 (m, 2H), 7.14 (m, 1H), 6.44 (s, 1H), 6.27 (s, 1H).		3.3	>3000	A
18	^1H NMR (DMSO-d_6): 12.92 (s, 1H), 10.93 (s, 1H), 8.72 (s, 1H), 8.07 (s, 1H), 7.64 (m, 1H), 7.53 (m, 1H), 6.42 (s, 1H), 6.24 (s, 1H).		17	>3000	A
19	5.26 (B)	306	122	>3000	A
20	7.70 (B)	333 (^{79}Br)	25	>3000	A

No.	HPLC min (method)	MS (MH^+)	ER-β K_i nM	ER-α K_i nM	Synthetic Route
21	7.55 (B)	289 (^{35}Cl)	42	>3000	A
22			50	>3000	*
23	5.20 (B)	269	0.5	200	A
24	4.91 (B)	273	3.3	>3000	A
25	6.07 (B)	323	10	321	Note a)
26			3.7	1000	*
27	5.43 (B)	271	5.7	3000	Note b)
28	^1H NMR (DMSO-d_6): 10.47 (m, 1H), 9.55 (m, 1H), 7.67 (d, 1H), 7.1-6.7 (m, 6H), 2.22 (m, 3H); MS: 269		12	322	B
29	5.57 (B)	283	4	80	B
30	6.01 (B)	239	140	>3000	B
31	^1H NMR (DMSO-d_6): 10.68 (s, 1H), 8.44 (s, 1H), 7.75 (m, 1H), 7.60 (m, 2H), 7.16 (m, 1H), 6.87 (dd, 1H), 6.81 (m, 1H); MS: 245		108	>3000	B
32			33	>3000	*
33	^1H NMR (DMSO d-6): 12.66 (s, 1H), 10.98 (s, 1H), 8.42 (s, 1H), 7.48 (m, 2H), 7.27 (m, 2H), 6.44 (d, 1H, J= 2.1 Hz), 6.26 (d, 1H, J= 2.1 Hz); MS: 273		50	>3000	A
34			9.5	95	*
35			19	50	*
36			0.33	88	*
37	^1H NMR (DMSO d-6): 9.61 (s, 1H), 9.52 (s, 1H), 7.26 (d, 1H, J= 2.7 Hz), 7.21-7.13 (m, 3H), 6.99 (dd, 1H, J= 8.1 Hz, J'= 2.7 Hz), 6.71 (d, 2H, J= 8.4 Hz), 3.26 (m, 1H), 3.07-2.80 (m, 3H), 2.64 (m, 1H); MS: 253 $(M-H)^-$		0.73	75	Note c)

No.	HPLC min (method)	MS (MH^+)	ER-β K_i nM	ER-α K_i nM	Synthetic Route
38	^{1}H NMR (DMSO d-6): 10.52 (s, 1H), 9.64 (s, 1H), 8.03 (s, 1H), 7.55 (m, 3H), 6.85-6.70 (m, 4H); MS: 255		4.9	220	B
39	^{1}H NMR (DMSO d-6): 10.63 (s, 1H), 10.33 (s, 1H), 9.60 (s, 1H), 7.95 (s, 1H), 7.50 (d, 2H, J= 8.4 Hz), 6.80 (d, 2H, J= 8.4 Hz), 6.28 (s, 1H), 6.22 (s, 1H); MS: 271		79	>3000	B
40	^{1}H NMR (DMSO d-6): 10.18 (s, 1H), 9.73 (s, 1H), 8.08 (s, 1H), 7.60 (d, 2H, J= 8.4 Hz), 7.17 (m, 2H), 7.06 (m, 1H), 6.85 (d, 2H, J= 8.4 Hz); MS: 255		104	>3000	B
41	^{1}H NMR (DMSO d-6): 9.72 (s, 2H), 8.05 (s, 1H), 7.58 (d, 2H, J= 8.4 Hz), 7.25 (d, 1H, J= 8.7 Hz), 7.07 (d, 1H, J= 2.7 Hz), 7.00 (dd, 1H, J= 8.4 Hz, J'= 2.7 Hz), 6.84 (d, 2H, J= 8.4 Hz); MS: 255		4.6	3000	B
42	^{1}H NMR (DMSO d-6): 10.56 (s, 1H), 7.50 (d, 2H, J= 7.8 Hz), 7.42 (d, 1H, J= 8.7 Hz), 7.33 (d, 2H, J= 7.8 Hz), 6.84 (dd, 1H, J= 7.8 Hz, J'= 2.1 Hz), 6.75 (d, 1H, J= 2.1 Hz), 2.21 (s, 3H); MS: 287 (^{35}Cl)		51	>3000	B
43	^{1}H NMR (DMSO d-6): 10.36 (s, 1H), 9.55 (s, 1H), 7.49 (d, 1H, J= 9 Hz), 7.08 (d, 2H, J= 8.7 Hz), 6.87 (d, 1H, J= 9 Hz), 6.81 (d, 2H, J= 8.7 Hz), 2.21 (s, 3H), 2.19 (s, 3H); MS: 283		24	500	B
44	^{1}H NMR (DMSO d-6): 11.11 (s, 1H), 7.93 (d, 1H, J= 8.7 Hz), 7.16 (d, 2H, J= 8.4 Hz), 7.03-6.93 (m, 4H), 4.66 (m, 1H), 1.30 (d, 6H, J= 6Hz); MS: 365		118	3000	Note a)

No.	HPLC min (method)	MS (MH^+)	ER-β K_i nM	ER-α K_i nM	Synthetic Route
45	^1H NMR (DMSO d-6): 10.39 (s, 1H), 7.78 (d, 1H, J= 8.4 Hz), 7.42 (m, 2H), 7.28 (t, 1H, J= 7.8 Hz), 7.19 (d, 1H, J= 7.8 Hz), 6.75 (dd, 1H, J= 8.4 Hz, J'= 2.4 Hz), 6.69 (d, 1H, J= 2.4 Hz), 3.86 (m, 1H), 3.00 (m, 1H), 2.85 (m, 1H), 2.4-2.1 (m, 2H); MS: 317 (^{79}Br)		116	3000	Note b)
46			2	155	*

* compound is commercially available.

Note a): Prepared according to method A; the cyclization step was done using trifluoroacetic anhydride according to J. Med. Chem. 1992, 35, 3519.

Note b): Prepared by cyclization of the corresponding 2,4-diarylbutyric acid with $POCl_3$, and subsequent demethylation of the methoxy ethers according to the method developed in J. Org. Chem. 1946, 11, 34.

Note c): Prepared according to Aust. J. Chem. 1978, 31, 1011.

CLAIMS:

1. A method for treating a disease associated with the estrogen receptor-β, comprising the step of administering a therapeutically-effective amount of a compound that satisfies the equation:

$(K_{i\alpha A}/Ki_{bA})/(K_{i\alpha E}/K_{ibE}) > 1$,

wherein

$K_{i\alpha A}$ is the K_i value for the agonist in ER-α;

$K_{i\beta A}$ is the K_i value for the agonist in ER-β;

$K_{i\alpha E}$ is the K_i value for estrogen in ER-α; and

$K_{i\beta E}$ is the K_i value for estrogen in ER-β.

2. The method according to Claim 1, wherein the compound satisfies the equation: $(K_{i\alpha A}/Ki_{\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 100$.

3. The method according to Claim 2, wherein the disease to be treated is selected from the group consisting of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer.

4. The method according to Claim 3, wherein the compound has the formula:



wherein:

L^1 is -C(=O)-, $=C(R^6)$-, $-CH(R^6)$-, O, S, or NR^a;

L^2 is =C- or -CH-;

L^3 is $=C(R^6)$-, $-CH(R^6)$- or -C(=O)-;

L^4 is -C(=O)-, CH_2, O, S, or NR^a;

wherein:

when L^1 is -C(=O)-, L^4 is CH_2, O, S, or NR^a;

when L^4 is -C(=O)-, L^1 is CH_2, O, S, or NR^a;

when L^3 is -C(=O)-, L^1 is $=C(R^6)$- or $-CH(R^6)$-, and L^4 is O or NR^a

when L^1 is $=C(R^6)$-, L^2 is =C-;

when L^1 is $-CH(R^6)$-, L^2 is -CH-;

when L^3 is $=C(R^6)$-, L^2 is =C-; and

when L^3 is $-CH(R^6)$-, L^2 is -CH-;

R^a is, independently, at each occurrence, H or $(C_1$-$C_5)$alkyl;

R^1 is phenyl, substituted phenyl or Het;

R^2, R^3, R^4 and R^5 are independently selected from the group consisting of $-R^a$, $-OR^a$, $-SR^a$, $-NR^aR^a$, $-NC(=O)R^a$, $-NS(=O)R^a$, $-NS(=O)_2R^a$, halogen, cyano, $-CF_3$, $-CO_2R^a$, -C(=O)R^a, -C(=O)NHR^a, nitro, $-S(=O)R^a$ and $-S(=O)_2R^a$;

R^6 is H, $(C_1$-$C_5)$alkyl, phenyl or CF_3; and

wherein, when L^1 is -C(=O)-, and R^2 is hydroxy or hydrogen, and R^3 is hydrogen, and R^4 is hydroxy, and R^5 is hydrogen, and R^6 is hydrogen then R^1 is not para-phenol; and

any pharmaceutically-acceptable salt thereof.

5. The method according to Claim 4, wherein R^1 is Het.

6. The method according to Claim 4, wherein:

R^1 has the structure:



wherein:

R^7 is H, Cl or methyl;

R^8 is Br, Cl, F, R^a, OR^a or allyl;

R^9 is H, OH, NH_2, Br or Cl; and

R^{10} is H or methyl; or

R^8 and R^9 combine to form $-OCH_2O-$; or

R^1 is a substituted or unsubstituted version of one of the following:



7. The method according to any one of Claims 6, wherein the disease is Alzheimer's disease or depressive disorders.

8. The method according to Claim 6 wherein R^2, R^3, R^4 and R^5 are independently selected from the group consisting of R^a, OR^a, NR^a_2, $NC(=O)R^a$, CF_3 and halogen.

9. The method according to Claim 8 wherein:

R^2 is hydroxyl or hydrogen;

R^3 is hydrogen or methyl;

R^4 is hydroxyl or hydrogen; and

R^5 is hydrogen or hydroxyl.

10. The method according to Claim 8 wherein L^4 is -C(=O)-.

11. The method according to Claim 8 wherein L^3 is -C(=O)-.

12. The method according to Claim 8 wherein L^1 is -C(=O)-.

13. The method according to Claim 9 wherein R^1 is an unsubstituted version of